Working Groups

Latest News

IJAA Editor's Choice

May's Editor's Choice articles are free for a limited time!

Read More
Travel Grants Available!

ISAC is now accepting travel grant applications to attend 31st ICC-4th GCCMID....

Read More


Current Officers

F Amer


Fatma Amer

A Hoepelman


Andy Hoepelman

K Ayaz


Khan Fariduddin Mohammad Ayaz

Z Sekawi


Zamberi Sekawi

All Members

Mamun Al-Mahtab (Bangladesh)
Joop Arends (The Netherlands)
Shafiqul Bari (Bangladesh)
Junaid Bhai (Bangladesh)
Rehab Elsaid (Egypt)
Hakan Erdem (Turkey)
N. Furusyo (Japan)
Noha Hammad (Egypt)
D. Januszkiewicz-Lewandowska (Poland)
Lanjuan Li (China)
T. Lizuka (Japan)
Aouni Mahjoub (Tunisia)
Mojca Matičič (Slovenia)
Syed Ghulam Mogni Mowla (Bangladesh)
Monkez Moteia (Egypt)
Ghada Nasr (Egypt)
N. Nazia (Bangladesh)
Kemal Ozden (Turkey)
Fazle Rabbi Chowdhury (Bangladesh)
W. F. Tang (China)
Adnan Toumi (Tunisia)
P. Zhao (China)

How to Join

Members of an ISAC Member Society are eligible to join any of our Working Groups. If you are a member and would like to join this group, please contact the Chairperson and Secretary (if applicable).

Aims and Objectives

Hepatitis is a serious hazard, leading to morbidity and mortality, that affects the quality of life. There are many causes of hepatitis, both infectious and non-infectious. Hepatitis can be acute or chronic. Infectious agents account for the majority of acute cases: hepatitis C alone accounts for approximately 20% of acute cases. Fourteen other families of viruses are also responsible for acute hepatitis. Moreover, bacteria, protozoa, parasites, fungi and algae can similarly cause acute hepatitis. With regards to chronic hepatitis, in addition to many other causes, viral hepatitis (hepatitis B with or without hepatitis D, hepatitis C, and hepatitis E) is of special concern. Autoimmune disorders can also lead to chronic hepatitis. We are all quite cognizant that nearly 170 million people worldwide are suffering from chronic hepatitis C virus (HCV) infections. Likewise, it is estimated that the global reservoir of HCV infected individuals is on a steady increase, which is not limited to developing countries. In the USA, 18,000 new HCV infections occur each year, as reported by the Centers for Disease Control and Prevention (CDC), which corresponds to approximately one new case every 30 minutes.

The aim of the Hepatitis Working Group is to work together at an international level, in multiple areas related to hepatitis with regards to education and research activities. Special emphasize is to be placed on clinical trials for treatment of HCV patients using newly developed direct-acting antivirals (DAA), and on HCV genotypes which have not been tackled by most of the ongoing studies, e. g., genotype 4.


  • To involve junior colleagues. When the enthusiasm and creative capabilities of younger colleagues are combined with the experience and wisdom of senior colleagues, wonderful things can be accomplished.
  • To hold “Hepatitis Symposiums” presented by members of the Hepatitis Working Group in all future meetings if possible, whether national, regional or international.
  • To make intensive fundraising efforts.
  • To carry out a study about prevalence and risk factors of asymptomatic hepatitis C virus infection in children. Following the availability of the new DAAs, perhaps identification of HCV early in childhood can alter the course of the disease. It is also important to take into account the long-term morbidity of the disease. The aim of this study is to identify the prevalence and possible risk factors of asymptomatic HCV infection in children and to detect the underlying signs and symptoms of liver disease associated with asymptomatic HCV in this category of patients.




December 2015 National Conference on Tropical Medicine & Toxicology, Cox Bazar, Bangladesh
November 2015 6th SEEC. Thessaloniki
July 2015 World Congress on Hepatitis, Orlando, Florida
April 2015 Annual Conference of Zagazig Faculty of Medicine
December 2014 3rd National Conference on Tropical Medicine & Toxicology, Sylhet, Bangladesh
October 2014 5th SEEC for Chemotherapy and Infection, Bled, Slovenia
September 2014  Towards HCV-Free Community Conference, Zagazig, Egypt.
April 2014  The 3rd Conference of the Federation of Arab Societies of Clinical Microbiology and Infectious Diseases & The 10th Conference of Arab Alliance for Prudent Use of Antimicrobial Agents (ArAPUA), Dead Sea, Jordan. 



Projects / Publications

Epidemiology of Hepatitis C Virus Infection in Egypt.  Amer F, Yousif, M. International Journal of TROPICAL DISEASE & Health. 2015: 7(3): 119-131.
Immunological mechanisms controlling hepatitis C virus infection Amer F. Asian Pacific Journal of Tropical Disease. 2015: 5(2): 85-90
Immune-based strategies for treatment and prevention of hepatitis C virus infection. The International Arabic Journal of Antimicrobial Agents. 2014: 1


Last updated: November 21st-2018